Clinical studies have already incorporated BETi into the treatment of GBM.[17] In this study, we selected the BET inhibitor (BETi) Birabresib, which is under clinical trials for GBM (clinicaltrials.gov, accessed May 2024). The gene discussed is DNER; the disease is glioblastoma.